PRTCL / Peptides / Tirzepatide vs Retatrutide
Comparison · Updated September 2026

Tirzepatide vs Retatrutide.

Tirzepatide is an FDA-approved dual agonist (GIP and GLP-1). Retatrutide is an investigational triple agonist from the same company that adds a third target, glucagon. Retatrutide has posted larger average weight loss in its Phase 3 trials, but no trial has compared the two directly, and Retatrutide is not approved.

Side by side
TirzepatideRetatrutide
Online nickname"GLP-2T""GLP-3R"
How it worksDual GIP and GLP-1 receptor agonistTriple GIP, GLP-1 and glucagon receptor agonist
MakerEli LillyEli Lilly
US statusFDA-approved (Mounjaro, Zepbound)Investigational, clinical trials only
Key obesity trial resultSURMOUNT-5: 20.2% average at 72 weeks (10 or 15 mg)TRIUMPH-1: up to 25.0% average at 80 weeks (12 mg)
How it is takenWeekly injectionWeekly injection in trials

Why the numbers cannot be compared directly

The trials enrolled different people, ran for different lengths of time and used different doses. A cross-trial comparison can suggest a difference but cannot prove one; only a head-to-head trial can, and none has been reported as of September 2026.

Where Retatrutide stands

Eli Lilly reported TRIUMPH-1 in May 2026: at 80 weeks average weight loss was 17.6%, 23.7% and 25.0% on 4, 9 and 12 mg, against 3.9% on placebo. TRIUMPH-2 (with type 2 diabetes) and TRIUMPH-3 (with cardiovascular disease) followed in July 2026 at up to 20.8% and 22.6%. Lilly has said it plans to file with the FDA in early 2027. Until approval, it is legally available only inside clinical trials; products sold online as "Retatrutide" or "GLP-3R" are unapproved and unregulated.

Tracking either one

For Tirzepatide: the injection day, each dose step, site rotation and supply. For a Retatrutide trial: study visit dates, your assigned dose, and weight and activity to bring to the study team.

Not medical advice. This page compares published facts and trial averages. It does not recommend any medicine or dose; that decision belongs to you and a licensed prescriber.
Sources
Related

All peptides · GLP-1 tracker · Peptide calculator

Questions worth answering

Common questions.

Is Retatrutide stronger than Tirzepatide?

Retatrutide has shown larger average weight loss in its own trials (up to 25.0% at 80 weeks in TRIUMPH-1) than Tirzepatide in its trials (20.2% at 72 weeks in SURMOUNT-5), but no head-to-head trial exists, so a direct claim cannot be made.

Is Retatrutide available?

Not outside clinical trials. As of September 2026 it is investigational and not approved anywhere.

When will Retatrutide be approved?

Eli Lilly has said it plans to submit it to the FDA in early 2027. Approval timing after that is up to the FDA.

What do "GLP-2T" and "GLP-3R" mean?

They are online nicknames for Tirzepatide and Retatrutide, counting the hormone receptors each one targets (two and three). They are not official names, and neither drug is a GLP-2 or GLP-3 medicine.

Can PRTCL track a clinical-trial protocol?

Yes. Log the weekly dose, injection day and site, and keep weight and activity from Health Connect alongside it.

Be informed. Every claim on this page links to its source. Read the studies, do your own research, and talk to a licensed healthcare provider before you start, stop or change anything. PRTCL tracks your protocol; it does not give medical advice.
Start with one protocol

Track it in one system.

PRTCL runs peptides, supplements, nutrition and training together, with reminders at the times you set, reconstitution math, site rotation and inventory that counts itself down. Launching on Android and iPhone the same day. Join the waitlist and enter the draw for one of 57 lifetime Premium subscriptions.